From the Journals

Genetic Risk for Gout Raises Risk for Cardiovascular Disease Independent of Urate Level


 

LIMITATIONS:

The definitions of lifestyle and metabolic syndrome were different in each cohort, which may have affected the findings. Data on lifestyle behaviors and metabolic health statuses were collected at enrollment, but these variables may have changed during the follow-up period, which potentially introduced bias into the results. This study was not able to establish causality between genetic predisposition to gout and the incident risk for CVD.

DISCLOSURES:

This study was supported by the National Institute of General Medical Sciences and the National Research Foundation of Korea. The authors declared no competing interests.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

ALL-HEART: No benefit of allopurinol in ischemic heart disease
MDedge Cardiology
Poor control of serum urate linked to cardiovascular risk in patients with gout
MDedge Cardiology
Teamwork guides cardio-rheumatology clinics that care for unique patient population
MDedge Cardiology
FDA OKs low-dose colchicine for broad CV indication
MDedge Cardiology
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
MDedge Cardiology
Evidence Grows for SGLT2 Inhibitors in Rheumatology
MDedge Cardiology
Gout Increases the Risk for a Wide Range of Cardiovascular Diseases
MDedge Cardiology
Neutrophils Take Center Stage in Growing Understanding of Colchicine’s Role in Treating Atherosclerotic Cardiovascular Disease
MDedge Cardiology
Colchicine: A New Tool for Ischemic Stroke, CVD Event Recurrence?
MDedge Cardiology
Analysis of Colchicine’s Drug-Drug Interactions Finds Little Risk
MDedge Cardiology